clinical trial · NCT06919939
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
University of Miami·phase2·recruiting·n = 26
Large B-cell LymphomaRelapseEpcoritamabLoncastuximab Tesirine
brief summary
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
started
Jan 7, 2026
primary completion
Jan 7, 2031
completion
Jan 7, 2031
last updated
Mar 2, 2026
official title
Phase 2 Study of Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol